Amelioration of Inflammatory Arthritis Targeting the Pre-ligand Assembly Domain (PLAD) of Tumor Necrosis Factor Receptors
Posted Jun 15 2010 5:00pm
Description of Invention: The invention relates to compositions of matter and methods for treating arthritis by modulating Tumor Necrosis Factor Alpha (TNF-alpha) signaling. TNF-alpha plays a key role in the pathogenesis of numerous diseases including rheumatoid and septic arthritis, and other autoimmune and inflammatory diseases. TNF-alpha mediates its effects through receptors that contain a Pre-ligand Assembly Domain (PLAD). The inventors have discovered compounds that interfere with PLAD can block the effects of TNF-alpha in vitro. Treatment of mice with these compounds in vivo ameliorated disease in several models of arthritis. Therefore, the compositions and methods of the current invention may lead to novel arthritis treatments.
Related Technologies: US, Patent No. 7,148,061, Issued 12 Dec 2006, Reference No. E-095-2000/0 EIR, Reference No. E-095-2000/0 US, Application No. 60/181,909 filed 11 Feb 2000, Reference No. E-095-2000/0 US, Application No. 11/637,272 filed 12 Dec 2006, Reference No. E-095-2000/0 PCT, Application No. PCT/US01/04125 filed 09 Feb 2001, Reference No. E-095-2000/0
Licensing Status: In addition to licensing, the technology is available for further development through collaborative research opportunities with the inventors.
Portfolios: Cancer Cancer - Therapeutics Cancer - Research Materials In-vivo Data
For Additional Information Please Contact: Whitney Hastings NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: email@example.com Phone: 301-451-7337 Fax: 301-402-0220